Journal of Bone and Mineral Metabolism

, Volume 24, Issue 6, pp 434–438

The kidney and bone metabolism: Nephrologists' point of view

  • Masafumi Fukagawa
  • Yasuhiro Hamada
  • Shohei Nakanishi
  • Motoko Tanaka
REVIEW ARTICLE

Abstract

The kidney plays an important role in the regulatory system for bone and mineral metabolism. In chronic kidney disease (CKD), various abnormalities, recently named CKD-mineral and bone disorder (CKD-MBD), may develop in this system. The optimal management of CKD-MBD should be achieved without increasing the risk of metastatic calcification, including that of blood vessels. Thus, it is quite important to identify severe cases of hyperparathyroidism refractory to medical therapy. The size of the parathyroid glands, serum levels of fibroblast growth factor (FGF)23, and, possibly, the overproduction of a novel form of parathyroid hormone (PTH), serve as useful markers for this purpose. Adynamic bone disease with low buffering capacity for calcium is another major cause of hypercalcemia in dialysis patients. Our recent studies suggest that indoxyl sulfate accumulated in uremic serum is responsible for the suppression of osteoblastic function. In order to maintain the bone quality in patients with CKD, bone changes due to aging, menopause, and malnutrition need to be considered by nephrolgists and non-nephrologists in collaboration.

Key words

kidney chronic kidney disease CKD-MBD parathyroid PTH FGF23 indoxyl sulfate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fukagawa, M, Akizawa, T 2006Calcium abnormalities of dialysis patientsJ Bone Miner Metab24160PubMedCrossRefGoogle Scholar
  2. 2.
    Malluche, H, Faugere, MC 1990Renal bone disease 1990: an unmet challenge for the nephrologistsKidney Int38193211PubMedGoogle Scholar
  3. 3.
    Patient Registration Committee, Japanese Society for Dialysis Therapy2005An Overview of regular dialysis treatment in Japan as of 31 December 2003Ther Apher Dial9431458CrossRefGoogle Scholar
  4. 4.
    Goodman, WG, Goldin, J, Kuison, BD, Yoon, C, Gales, B, Sider, D, Wang, Y, Chung, J, Emerick, A, Greaser, L, Elashoff, RM, Salusky, IB 2003Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysisN Engl J Med34214781483CrossRefGoogle Scholar
  5. 5.
    Moe, S Drueke, T Cunningham, J Goodman, W Martin, K Olgaard, K Ott, S Sprague, S Lameire, N Eknoyan, G Kidney Disease: Improving Global Outcome (KDIGO)2006Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO)Kidney Int6919451953PubMedCrossRefGoogle Scholar
  6. 6.
    Olgaard, K, Lewin, E 2006Can hyperparathyroid bone disease be arrested or reversed?Clin J Am Soc Nephrol1367373CrossRefPubMedGoogle Scholar
  7. 7.
    Slatopolsky, E, Caglar, S, Gradowska, L, Canturbury, J, Reiss, E, Bricker, NS 1972On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intakeKidney Int2147151PubMedGoogle Scholar
  8. 8.
    Slatopolsky, E, Finch, J, Denda, M, Ritter, C, Zhong, M, Dusso, A, MacDonald, PN, Brown, AJ 1996Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitroJ Clin Invest9725342540PubMedGoogle Scholar
  9. 9.
    Portale, AA, Booth, BE, Halloran, BP, Morris, RC,Jr 1984Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiencyJ Clin Invest7315801589PubMedGoogle Scholar
  10. 10.
    Shigematsu, T, Kazama, JJ, Yamashita, T, Fukumoto, S, Hosoya, T, Gejyo, F, Fukagawa, M 2004Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiencyAm J Kidney Dis44250256PubMedCrossRefGoogle Scholar
  11. 11.
    Fukagawa, M, Nakanishi, S, Kazama, JJ 2006Basic and clinical aspects of parathyroid hyperplasia in chronic kidney diseaseKidney Int70S3S7CrossRefGoogle Scholar
  12. 12.
    Drüeke, TB 2000Cell biology of parathyroid gland hyperplasia in chronic renal failureJ Am Soc Nephrol1111411152PubMedGoogle Scholar
  13. 13.
    Tominaga, Y, Tanaka, Y, Sato, K, Nagasaka, T, Takagi, H 1997Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidismSemin Surg Oncol137886PubMedCrossRefGoogle Scholar
  14. 14.
    Fukuda, N, Tanaka, H, Tominaga, Y, Fukagawa, M, Kurokawa, K, Seino, Y 1993Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patientsJ Clin Invest9214361443PubMedCrossRefGoogle Scholar
  15. 15.
    Kifor, O, Moore, FD,Jr, Wang, P, Goldstein, M, Vassilev, P, Kifor, I, Hebert, SC, Brown, EM 1996Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidismJ Clin Endocrinol Metab8115981606PubMedCrossRefGoogle Scholar
  16. 16.
    Tominaga, Y, Kohara, S, Namii, Y, Nagasaka, T, Haba, T, Uchida, K, Numano, M, Tanaka, Y, Takagi, H 1996Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidismWorld J Surg20744750PubMedCrossRefGoogle Scholar
  17. 17.
    Cozzolino, M, Lu, Y, Sato, T, Yang, J, Suarez, IG, Brancaccio, D, Slatopolsky, E, Dusso, A 2005A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney diseaseAm J Physiol Renal Physiol289F1096F1102PubMedCrossRefGoogle Scholar
  18. 18.
    Dusso, A, Sato, T, Arcidiacono, MV, Hernandez, DA, Yang, J, Gonzarez-Suarez, I, Tominaga, Y, Slatopolsky, E 2006Pathogenic mechanisms for parathyroid hyperplasiaKidney Int70S8S11CrossRefGoogle Scholar
  19. 19.
    National Kidney Foundation2003K/DOQI Clinical guidelines for bone metabolism and disease in chronic kidney diseaseAm J Kidney Dis42S1S202Google Scholar
  20. 20.
    Fukagawa, M, Kitaoka, M, Yi, H, Fukuda, N, Matsumoto, T, Ogata, E, Kitaoka, M, Harada, S, Sekine, NM, Matsumoto, T, Kurokawa, K 1994Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patientNephron68221228PubMedCrossRefGoogle Scholar
  21. 21.
    Kato, N, Nakayama, M, Shigematsu, T, Yamamoto, H, Sano, K, Saito, I, Nakano, H, Kasai, K, Kubo, H, Sakai, S, Kawaguchi, Y, Hosoya, T 2000Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidismAm J Kidney Dis354665468Google Scholar
  22. 22.
    Okuno, S, Ishimura, E, Kitatani, K, Chou, H, Nagasue, K, Maekawa, K, Izumotani, T, Yamakawa, T, Imanishi, Y, Shoji, T, Inaba, M, Nishizawa, Y 2003Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidismNephrol Dial Transplant1826132621PubMedCrossRefGoogle Scholar
  23. 23.
    Tominaga, Y Inaguma, D Matsuoka, S Tahara, H Kukita, K Kurihara, S Onoda, N Tsuruta, Y Tsutsui, S Ohta, K Kuwahara, M Tanaka, M Nishizawa, Y PTG study group2006Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidismTher Apher Dial10198204PubMedCrossRefGoogle Scholar
  24. 24.
    Onoda, N, Kurihara, S, Sakurai, Y, Owada, K, Osono, E, Adachi, H, Suga, M, Yoneshima, H 2003Evaluation of blood supply to parathyroid glands in secondary hyperparathyroidism compared with histopathologyNephrol Dial Transplant18iii34iii37PubMedGoogle Scholar
  25. 25.
    Nakamura, M, Fuchinoue, S, Teraoka, S 2003Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidismAm J Kidney Dis42739745PubMedCrossRefGoogle Scholar
  26. 26.
    Shimada, T, Mizutani, S, Muto, T, Yoneya, T, Hino, R, Takeda, S, Takeuchi, Y, Fujita, T, Fukumoto, S, Yamashita, T 2001Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProc Natl Acad Sci USA9865006505PubMedCrossRefGoogle Scholar
  27. 27.
    Fukagawa, M, Kazama, JJ 2005Editorial comments: With or without the kidney: the role of FGF23 in CKDNephrol Dial Transplant2012951298PubMedCrossRefGoogle Scholar
  28. 28.
    Nakanishi, S, Kazama, JJ, Nii-Kono, T, Omori, K, Yamashita, T, Fukumoto, S, Gejyo, F, Shigematsu, T, Fukagawa, M 2005Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patientsKidney Int6711711178PubMedCrossRefGoogle Scholar
  29. 29.
    Kazama, JJ, Sato, F, Omori, K, Hama, H, Yamamoto, S, Maruyama, H, Narita, I, Gejyo, F, Yamashita, T, Fukumoto, S, Fukagawa, M 2005Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patientsKidney Int6711201125PubMedCrossRefGoogle Scholar
  30. 30.
    Nishi, H, Nii-Kono, T, Nakanishi, S, Yamazaki, Y, Yamashita, T, Fukumoto, S, Ikeda, K, Fujimori, A, Fukagawa, M 2005Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidismNephron Clin Pract101c94c99PubMedCrossRefGoogle Scholar
  31. 31.
    Kurosu, H, Ogawa, Y, Miyoshi, M, Yamamoto, M, Nandi, A, Rosenblatt, KP, Baum, MG, Schiavi, S, Hu, MC, Moe, OW, Kuro-o, M 2006Regulation of fibroblast growh factor-23 signalling by klothoJ Biol Chem28161206123PubMedCrossRefGoogle Scholar
  32. 32.
    Brown, RC, Aston, JP, Weeks, I, Woodhead, JS 1987Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assayJ Clin Endocrinol Metab65407414PubMedCrossRefGoogle Scholar
  33. 33.
    John, MR, Goodman, WG, Gao, P, Cantor, TL, Salusky, IB, Juppner, H 1999A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failureJ Clin Endocrinol Metab8442874290PubMedCrossRefGoogle Scholar
  34. 34.
    Nakanishi, S, Kazama, JJ, Shigematsu, T, Iwasaki, Y, Cantor, TL, Kurosawa, T, Fukagawa, M 2001Comparison of intact PTH assay and whole PTH assay in long-term dialysis patientsAm J Kidney Dis38S172174PubMedGoogle Scholar
  35. 35.
    Tanaka, M, Itoh, K, Matsushita, K, Matsushita, K, Fujii, H, Fukagawa, M 2005Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidismClin Nephrol646972PubMedGoogle Scholar
  36. 36.
    Arakawa, T, D'Amour, , Sakai, M, Katsumoto, H, Igaki, N, Goto, T, Cantor, T, Fukagawa, M 2006Production and secretion of a novel molecular form of PTH from the most severe type of parathyroid hyperplasia in uremiaClin J Am Soc Nephrol1525531CrossRefPubMedGoogle Scholar
  37. 37.
    D'Amour, P, Brossard, JH, Rousseau, L, Roy, L, Gao, P, Cantor, T 2003Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidismClin Chem4920372044PubMedCrossRefGoogle Scholar
  38. 38.
    Rakel, A, Brossard, JH, Patenaude, J-V, Albert, C, Nassif, E, Cantor, T, Rousseau, L, D'Amour, P 2005Overproduction of an amino-terminal form of PTH distinct from human PTH (1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgeryClin Endocrinol62721727CrossRefGoogle Scholar
  39. 39.
    Fukagawa, M, Kazama, JJ, Shigematsu, T 2002Management of the patients with advanced secondary hyperparathyroidism: the Japanese approachNephrol Dial Transplant1715531557PubMedCrossRefGoogle Scholar
  40. 40.
    Tanaka, M, Tominaga, Y, Sawatari, E, Itoh, K, Matsushita, K, Matsushita, K, Matsuoka, S, Ueki, T, Goto, N, Sato, T, Katayama, A, Haba, T, Uchida, K 2004Infarction of mediastinal parathyroid gland causing spontaneous remission of secondary hyperparathyroidismAm J Kidney Dis44762767PubMedCrossRefGoogle Scholar
  41. 41.
    Tanaka, M, Tominaga, Y, Itoh, K, Matsushita, K, Matsushita, K, Ueki, T, Goto, N, Sato, T, Kanayama, A, Haba, T, Uchida, K 2006Autoinfarction of the parathyroid gland diagnosed by power Doppler ultrasonography in a patient with secondary hyperparathyroidismNephrol Dial Transplant2110921095PubMedCrossRefGoogle Scholar
  42. 42.
    Fukagawa, M Kitaoka, M Tominaga, Y Akizawa, T Kakuta, T Onoda, N Koiwa, F Yumita, S Kurokawa, K Japanese Society for Parathyroid Intervention2003Guideline for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patientsNephrol Dial Transplant183133Google Scholar
  43. 43.
    Kitaoka, M, Fukagawa, M, Ogata, E, Kurokawa, K 1994Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patientsKidney Int4611101117PubMedGoogle Scholar
  44. 44.
    Kakuta, T, Fukagawa, M, Fujisaki, T, Hida, M, Suzuki, H, Sakai, H, Kurokawa, K, Saito, A 1999Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patientsAm J Kidney Dis3310911099PubMedGoogle Scholar
  45. 45.
    Kitaoka, M, Fukagawa, M, Fukuda, N, Yi, H, Kurokawa, K 1995Direct injections of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunctionNephrology1563568Google Scholar
  46. 46.
    Kitaoka, M, Onoda, N, Kitamura, H, Koiwa, F, Tanaka, M, Fukagawa, M 2003Percutaneous calcitriol injection therapy (PCIT) of secondary hyperparathyroidism: multicentre trialNephrol Dial Transplant183841Google Scholar
  47. 47.
    Shiizaki, K, Hatamura, I, Negi, S, Narukawa, N, Mizobuchi, M, Sakaguchi, T, Ooshima, A, Akizawa, T 2003Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremiaKidney Int649921003PubMedCrossRefGoogle Scholar
  48. 48.
    Shiizaki, K, Negi, S, Hatamura, I, Sakaguchi, T, Sagi, F, Kunimoto, K, Mizobuchi, M, Imazeki, I, Ooshima, A, Akizawa, T 2005Biochemical and cellular effect of direct maxacalcitol injection into parathyroid gland in uremic ratJ Am Soc Nephrol1697108PubMedCrossRefGoogle Scholar
  49. 49.
    Colloton, M, Shatzen, E, Miller, G, Stehman-Breen, C, Wada, M, Lacey, D, Martin, D 2005Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney Int67467476PubMedCrossRefGoogle Scholar
  50. 50.
    Fukagawa, M 2006Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?Nat Clin Pract Nephrol2248249PubMedCrossRefGoogle Scholar
  51. 51.
    Srinivas, TR, Schold, JD, Womer, KL, Kaplan, B, Howard, RJ, Bucci, CM, Meier-Kriesche, H 2006Improvement in hypercalcemia with cinacalcet after kidney transplantationClin J Am Soc Nephrol1323326CrossRefPubMedGoogle Scholar
  52. 52.
    Massry, SG, Coburn, JW, Lee, DB, Jowsey, J, Kleeman, CR 1973Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjectsAnn Intern Med78357364PubMedGoogle Scholar
  53. 53.
    Fukagawa, M, Kazama, JJ, Shigematsu, T 2001Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseasesAm J Kidney Dis38S152S155PubMedGoogle Scholar
  54. 54.
    Sherrard, DJ, Hercz, G, Pei, Y, Maloney, NA, Greenwood, C, Manuel, A, Saiphoo, C, Fenton, SS, Segre, GV 1993The spectrum of bone disease in end-stage renal failure—an evolving disorderKidney Int43436442PubMedGoogle Scholar
  55. 55.
    Goodman, WG, Ramirez, JA, Belin, TR, Chon, Y, Gales, B, Segre, GV, Salusky, IB 1994Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapyKidney Int4611601166PubMedGoogle Scholar
  56. 56.
    Atsumi, K, Kushida, K, Yamazaki, K, Shimizu, S, Ohmura, A, Inoue, T 1999Risk factors for vertebral fractures in renal osteodystrophyAm J Kidney Dis33287293PubMedGoogle Scholar
  57. 57.
    Coco, M, Rush, H 2000Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormoneAm J Kidney Dis3611151121PubMedGoogle Scholar
  58. 58.
    Kurz, P, Monier-Faugere, MC, Bognar, B, Werner, E, Roth, P, Vlachojannis, J, Malluche, HH 1994Evidence for abnormal calcium homeostasis in patients with adynamic bone diseaseKidney Int46855861PubMedGoogle Scholar
  59. 59.
    Quarles, LD, Lobaugh, B, Murphy, G 1992Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremiaJ Clin Endocrinol Metab75145150PubMedCrossRefGoogle Scholar
  60. 60.
    Monier-Faugere, MC, Geng, Z, Mawad, H, Friedler, RM, Gao, P, Cantor, TL, Malluche, HH 2001Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patientsKidney Int6014601468PubMedCrossRefGoogle Scholar
  61. 61.
    Friedman, P, Goodman, WG 2006PTH (1-84)/PTH (7-84): a balance of powerAm J Physiol Renal Physiol290F975F984PubMedCrossRefGoogle Scholar
  62. 62.
    Lund, RJ, Davies, MR, Brown, AJ, Hruska, KA 2004Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation modelJ Am Soc Nephrol15359369PubMedCrossRefGoogle Scholar
  63. 63.
    Iwasaki-Ishizuka, Y, Yamato, H, Nii-Kono, T, Fujieda, A, Uchida, M, Hosokawa, A, Motojima, M, Kurokawa, K, Fukagawa, M 2005Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of chronic renal failure with low turnover boneNephrol Dial Transplant2019041911PubMedCrossRefGoogle Scholar
  64. 64.
    Vanholder, R Smet, RD Glorieux, G Argiles, A Baurmeiter, U European Uremic Toxin Work Group (EUTox) et al. 2003Review on uremic toxins: classification, concentration, and interindividual variabilityKidney Int6319341943PubMedCrossRefGoogle Scholar
  65. 65.
    Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M (2006) Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uremic rats. Nephrol Dial Transplant doi:10.1093/ndt/gfl311Google Scholar
  66. 66.
    Enomoto, A, Takeda, M, Tojo, A, Sekine, T, Cha, SH, Khamdang, S, Takayama, F, Aoyama, I, Nakayama, S, Endou, H, Niwa, T 2002Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicityJ Am Soc Nephrol1317111720PubMedCrossRefGoogle Scholar
  67. 67.
    Boyle, WJ, Simonet, WS, Lacey, DL 2003Osteoclast differentiation and activationNature423337342PubMedCrossRefGoogle Scholar
  68. 68.
    Kazama, JJ, Shigematsu, T, Tsuda, E, Yano, K, Miura, M, Kawaguchi, Y, Gejyo, F, Kurokawa, K, Fukagawa, M 2002Increased circulating levels of osteoclastogenesis inhibitory factor/osteoprotegerin in patients with chronic renal failure: possible roles in skeletal resistance to PTH in uremiaAm J Kidney Dis39525532PubMedGoogle Scholar
  69. 69.
    Kazama, JJ, Omori, K, Yamamoto, S, Ito, Y, Maruyami, H, Narita, I, Gejyo, F, Iwasaki, Y, Fukagawa, M 2006Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidismTher Apher Dial10262266PubMedCrossRefGoogle Scholar
  70. 70.
    Tanaka, M, Itoh, K, Matsushita, K, Matsushita, K, Fukagawa, M 2005High serum estradiol concentrations in postmenopausal women with end-stage renal disease (letter)Clin Nephrol64394396PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Masafumi Fukagawa
    • 1
  • Yasuhiro Hamada
    • 1
  • Shohei Nakanishi
    • 1
    • 2
  • Motoko Tanaka
    • 3
  1. 1.Division of Nephrology and Dialysis CenterKobe University School of MedicineKobeJapan
  2. 2.Division of NephrologyToranomon Branch HospitalKawasakiJapan
  3. 3.Department of NephrologyAkebono ClinicKumamotoJapan

Personalised recommendations